Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Shares of Achieve Life Sciences, Inc. (ACHV) have gapped up nearly 20% Friday morning after the clinical-stage pharmaceutical company announced that its cytisinicline beat Pfizer's varenicline in smoking cessation study.


RTTNews | Sep 18, 2020 10:40AM EDT

10:40 Friday, September 18, 2020 (RTTNews.com) - Shares of Achieve Life Sciences, Inc. (ACHV) have gapped up nearly 20% Friday morning after the clinical-stage pharmaceutical company announced that its cytisinicline beat Pfizer's varenicline in smoking cessation study.

Achieve Life Sciences develops and commercializes cytisinicline for smoking cessation aids.

Cytisinicline is a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

The data were presented at the Society for Research on Nicotine and Tobacco European Annual Meeting.

The stock is currently trading 1% higher at $11.08. It has traded in the range of $4.51- $48.60 in the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3129844/stock-alert-achieve-life-sciences-opens-higher.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC